Merck gains EU backing to expand ENFLONSIA RSV use
Merck (MRK) received EU backing to expand ENFLONSIA's use to prevent RSV in high-risk children up to 24 months. The CHMP recommended approval, following its initial approval in April 2026. The Phase 3 trial included 276 children. The EU decision is expected within two months, with the FDA's target date set for March 2027.
How this was made
The 30-second read
Why it matters
The expanded indication could significantly increase the addressable market and drive incremental revenue, supporting Merck's broader infectious‑disease portfolio.
Market read
Regulatory progress on ENFLONSIA is a material catalyst for Merck's stock, with potential upside in both European and global markets.
What to watch
Reimbursement negotiations in Europe and competition from other RSV products may temper price gains.
Background
Merck's ENFLONSIA (clesrovimab) was approved for first‑season RSV prevention in 2025 (US) and 2026 (EU). The new recommendation extends use to a second RSV season for high‑risk children.
Ticker impact
EU CHMP recommendation to expand ENFLONSIA use for RSV prevention in children up to 24 months.
upward pressure as investors price in broader indication and future sales.
First‑time EU recommendation expands market size; Merck's share price typically reacts positively to such approvals.
Market effects
Boosts the RSV vaccine/antibody sector and may lift peers with similar pipelines.
Positive for European healthcare markets as a new pediatric indication is added.
Adds to Merck's global growth narrative, potentially influencing worldwide biotech sentiment.
Counterpoint
If EU approval stalls or faces post‑marketing issues, the upside could be limited.
Key entities
- CompanyMerck
Pharmaceutical company seeking expanded RSV indication.
- ProductENFLONSIA
Monoclonal antibody (clesrovimab) for RSV prevention.
